Cargando…

The STING agonist, DMXAA, reduces tumor vessels and enhances mesothelioma tumor antigen presentation yet blunts cytotoxic T cell function in a murine model

We assessed the murine Stimulator of Interferon Genes (STING) agonist, DMXAA, for anti-mesothelioma potential using the AE17-sOVA model that expresses ovalbumin (OVA) as a neo tumor antigen. Dose response experiments alongside testing different routes of administration identified a safe effective tr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Graham, Peter T., Nowak, Anna K., Cornwall, Scott M. J., Larma, Irma, Nelson, Delia J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9716460/ https://www.ncbi.nlm.nih.gov/pubmed/36466911 http://dx.doi.org/10.3389/fimmu.2022.969678

Ejemplares similares

Discovery of Novel STING Inhibitors Based on the Structure of the Mouse STING Agonist DMXAA
por: Chang, Jiajia, et al.
Publicado: (2023)

The STING agonist DMXAA triggers a cooperation between T lymphocytes and myeloid cells that leads to tumor regression
por: Weiss, Julia M., et al.
Publicado: (2017)

Flow cytometric characterization of tissue-resident lymphocytes after murine liver and heart transplantation
por: Prosser, Amy, et al.
Publicado: (2021)

Binding-Pocket and Lid-Region Substitutions Render Human STING Sensitive to the Species-Specific Drug DMXAA
por: Gao, Pu, et al.
Publicado: (2014)

DMXAA Causes Tumor Site-Specific Vascular Disruption in Murine Non-Small Cell Lung Cancer, and like the Endogenous Non-Canonical Cyclic Dinucleotide STING Agonist, 2′3′-cGAMP, Induces M2 Macrophage Repolarization
por: Downey, Charlene M., et al.
Publicado: (2014)

Remodeling tumor microenvironment by liposomal codelivery of DMXAA and simvastatin inhibits malignant melanoma progression
por: Rauca, Valentin-Florian, et al.
Publicado: (2021)

Rapid Copper Acquisition by Developing Murine Mesothelioma: Decreasing Bioavailable Copper Slows Tumor Growth, Normalizes Vessels and Promotes T Cell Infiltration
por: Crowe, Andrew, et al.
Publicado: (2013)

ExoSTING, an extracellular vesicle loaded with STING agonists, promotes tumor immune surveillance
por: Jang, Su Chul, et al.
Publicado: (2021)

The Proper Administration Sequence of Radiotherapy and Anti-Vascular Agent—DMXAA Is Essential to Inhibit the Growth of Melanoma Tumors
por: Drzyzga, Alina, et al.
Publicado: (2021)

Combination of anti-vascular agent - DMXAA and HIF-1α inhibitor - digoxin inhibits the growth of melanoma tumors
por: Smolarczyk, Ryszard, et al.
Publicado: (2018)

Tumor-targeted delivery of a STING agonist improves cancer immunotherapy
por: Wu, You-tong, et al.
Publicado: (2022)

Development of mesothelioma-specific oncolytic immunotherapy enabled by immunopeptidomics of murine and human mesothelioma tumors
por: Chiaro, Jacopo, et al.
Publicado: (2023)

Author Correction: Combination of anti-vascular agent - DMXAA and HIF-1α inhibitor - digoxin inhibits the growth of melanoma tumors
por: Smolarczyk, Ryszard, et al.
Publicado: (2020)

Polymersome-mediated cytosolic delivery of cyclic dinucleotide STING agonist enhances tumor immunotherapy
por: Zheng, Huan, et al.
Publicado: (2022)

Responsive Multivesicular Polymeric Nanovaccines that Codeliver STING Agonists and Neoantigens for Combination Tumor Immunotherapy
por: Su, Ting, et al.
Publicado: (2022)

Antitumor effect of anti-vascular therapy with STING agonist depends on the tumor microenvironment context
por: Czapla, Justyna, et al.
Publicado: (2023)

STING Agonists as Cancer Therapeutics
por: Amouzegar, Afsaneh, et al.
Publicado: (2021)

Cytogenomic characterization of three murine malignant mesothelioma tumor cell lines
por: Wahlbuhl, Eva, et al.
Publicado: (2020)

STING agonist inflames the pancreatic cancer immune microenvironment and reduces tumor burden in mouse models
por: Jing, Weiqing, et al.
Publicado: (2019)

Effective delivery of STING agonist using exosomes suppresses tumor growth and enhances antitumor immunity
por: McAndrews, Kathleen M., et al.
Publicado: (2021)

Photochemically controlled activation of STING by CAIX-targeting photocaged agonists to suppress tumor cell growth
por: Ding, Chunyong, et al.
Publicado: (2023)

Microenvironment-Dependent Gradient of CTL Exhaustion in the AE17sOVA Murine Mesothelioma Tumor Model
por: Hope, Jennifer L., et al.
Publicado: (2020)

The chemotherapeutic agent DMXAA potently and specifically activates the TBK1–IRF-3 signaling axis
por: Roberts, Zachary J., et al.
Publicado: (2007)

Dissection of stromal and cancer cell-derived signals in melanoma xenografts before and after treatment with DMXAA
por: Henare, K, et al.
Publicado: (2012)

Vascular disrupting agent DMXAA enhances the antitumor effects generated by therapeutic HPV DNA vaccines
por: Peng, Shiwen, et al.
Publicado: (2011)

The Chemotherapeutic Agent DMXAA as a Unique IRF3-Dependent Type-2 Vaccine Adjuvant
por: Tang, Choon Kit, et al.
Publicado: (2013)

Aging Leads to Increased Monocytes and Macrophages With Altered CSF-1 Receptor Expression and Earlier Tumor-Associated Macrophage Expansion in Murine Mesothelioma
por: Duong, Lelinh, et al.
Publicado: (2022)

Targeted delivery of a STING agonist to brain tumors using bioengineered protein nanoparticles for enhanced immunotherapy
por: Wang, Bin, et al.
Publicado: (2022)

Intratumoral STING Agonist Injection Combined with Irreversible Electroporation Delays Tumor Growth in a Model of Hepatocarcinoma
por: Lasarte-Cia, Aritz, et al.
Publicado: (2021)

Combination of photodynamic therapy and stimulator of interferon genes (STING) agonist inhibits colorectal tumor growth and recurrence
por: Hao, Yang, et al.
Publicado: (2023)

Tumor Regression upon Intratumoral and Subcutaneous Dosing of the STING Agonist ALG-031048 in Mouse Efficacy Models
por: Jekle, Andreas, et al.
Publicado: (2023)

HDAC Inhibition with Valproate Improves Direct Cytotoxicity of Monocytes against Mesothelioma Tumor Cells
por: Hoyos, Clotilde, et al.
Publicado: (2022)

Loss of antigen cross-presentation after complete tumor resection is associated with the generation of protective tumor-specific CD8(+) T-cell immunity
por: Brown, Matthew D., et al.
Publicado: (2012)

Trial watch: STING agonists in cancer therapy
por: Le Naour, Julie, et al.
Publicado: (2020)

Effects of STING stimulation on macrophages: STING agonists polarize into “classically” or “alternatively” activated macrophages?
por: Ohkuri, Takayuki, et al.
Publicado: (2017)

STING Agonist Combined to a Protein-Based Cancer Vaccine Potentiates Peripheral and Intra-Tumoral T Cell Immunity
por: Rossi, Matteo, et al.
Publicado: (2021)

STING agonist cGAMP enhances anti-tumor activity of CAR-NK cells against pancreatic cancer
por: Da, Yanyan, et al.
Publicado: (2022)

SHR1032, a novel STING agonist, stimulates anti-tumor immunity and directly induces AML apoptosis
por: Song, Chunying, et al.
Publicado: (2022)

Remodeling of Tumor Microenvironment by Nanozyme Combined cGAS–STING Signaling Pathway Agonist for Enhancing Cancer Immunotherapy
por: Dong, Wenpei, et al.
Publicado: (2023)

The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice
por: Zhao, L, et al.
Publicado: (2002)

Cannot write session to /tmp/vufind_sessions/sess_l8hph6sntva86r33sneda7gdn7